Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

NCT ID: NCT00150384

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine/Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated

Exclusion Criteria

* Subjects currently being treated with concomitant amlodipine and atorvastatin therapy, including Caduet
* Subjects with blood pressure at goal
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Huntsville, Alabama, United States

Site Status

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Los Angeles, California, United States

Site Status

Pfizer Investigational Site

Oakland, California, United States

Site Status

Pfizer Investigational Site

Pico Rivera, California, United States

Site Status

Pfizer Investigational Site

Bridgeport, Connecticut, United States

Site Status

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Pfizer Investigational Site

Aventura, Florida, United States

Site Status

Pfizer Investigational Site

Gainesville, Florida, United States

Site Status

Pfizer Investigational Site

Jacksonville, Florida, United States

Site Status

Pfizer Investigational Site

Orlando, Florida, United States

Site Status

Pfizer Investigational Site

Pensacola, Florida, United States

Site Status

Pfizer Investigational Site

Vero Beach, Florida, United States

Site Status

Pfizer Investigational Site

Athens, Georgia, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Augusta, Georgia, United States

Site Status

Pfizer Investigational Site

Columbus, Georgia, United States

Site Status

Pfizer Investigational Site

Columbus, Georgia, United States

Site Status

Pfizer Investigational Site

Decatur, Georgia, United States

Site Status

Pfizer Investigational Site

Lincolnton, Georgia, United States

Site Status

Pfizer Investigational Site

Savannah, Georgia, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Maywood, Illinois, United States

Site Status

Pfizer Investigational Site

Merrillville, Indiana, United States

Site Status

Pfizer Investigational Site

Overland Park, Kansas, United States

Site Status

Pfizer Investigational Site

Bossier City, Louisiana, United States

Site Status

Pfizer Investigational Site

New Orleans, Louisiana, United States

Site Status

Pfizer Investigational Site

New Orleans, Louisiana, United States

Site Status

Pfizer Investigational Site

Shreveport, Louisiana, United States

Site Status

Pfizer Investigational Site

Shreveport, Louisiana, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Columbia, Maryland, United States

Site Status

Pfizer Investigational Site

Randallstown, Maryland, United States

Site Status

Pfizer Investigational Site

Rockville, Maryland, United States

Site Status

Pfizer Investigational Site

Westminster, Maryland, United States

Site Status

Pfizer Investigational Site

Brockton, Massachusetts, United States

Site Status

Pfizer Investigational Site

Wellesley Hills, Massachusetts, United States

Site Status

Pfizer Investigational Site

Detroit, Michigan, United States

Site Status

Pfizer Investigational Site

Detroit, Michigan, United States

Site Status

Pfizer Investigational Site

Lansing, Michigan, United States

Site Status

Pfizer Investigational Site

Livonia, Michigan, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Cherry Hill, New Jersey, United States

Site Status

Pfizer Investigational Site

East Orange, New Jersey, United States

Site Status

Pfizer Investigational Site

Elizabeth, New Jersey, United States

Site Status

Pfizer Investigational Site

Hammonton, New Jersey, United States

Site Status

Pfizer Investigational Site

South Bound Brook, New Jersey, United States

Site Status

Pfizer Investigational Site

Voorhees Township, New Jersey, United States

Site Status

Pfizer Investigational Site

Woodbury, New Jersey, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

Buffalo, New York, United States

Site Status

Pfizer Investigational Site

Mineola, New York, United States

Site Status

Pfizer Investigational Site

Charlotte, North Carolina, United States

Site Status

Pfizer Investigational Site

Greenville, North Carolina, United States

Site Status

Pfizer Investigational Site

Monroe, North Carolina, United States

Site Status

Pfizer Investigational Site

Monroe, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Dayton, Ohio, United States

Site Status

Pfizer Investigational Site

Dayton, Ohio, United States

Site Status

Pfizer Investigational Site

Maumee, Ohio, United States

Site Status

Pfizer Investigational Site

Perrysburg, Ohio, United States

Site Status

Pfizer Investigational Site

Bensalem, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Bamberg, South Carolina, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Clinton, South Carolina, United States

Site Status

Pfizer Investigational Site

Mt. Pleasant, South Carolina, United States

Site Status

Pfizer Investigational Site

Simpsonville, South Carolina, United States

Site Status

Pfizer Investigational Site

Bartlett, Tennessee, United States

Site Status

Pfizer Investigational Site

Jackson, Tennessee, United States

Site Status

Pfizer Investigational Site

Beaumont, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Emporia, Virginia, United States

Site Status

Pfizer Investigational Site

Norfolk, Virginia, United States

Site Status

Pfizer Investigational Site

Norfolk, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Virginia Beach, Virginia, United States

Site Status

Pfizer Investigational Site

Virginia Beach, Virginia, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3841025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.